Sidley represented Leerink Partners and Oppenheimer & Co. as underwriters, in connection with Immuneering Corporation’s pricing of US$175 million underwritten public offering of Class A common stock and as placement agents, in connection with Immuneering’s concurrent US$25 million private placement of Class A common stock. Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive by developing a new category of cancer medicines, Deep Cyclic Inhibitors.
The Sidley deal team was led by Frank Rahmani, Craig Hilts, Ciko Kostian (Capital Markets) and included Sam Carvalho and Celine Gruaz (Emerging Companies and Venture Capital) and Torrey Cope, Kevin Sforza (Food, Drug and Medical Device), and Rachel Kleinberg (Tax).
